Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COOPER COMPANIES, INC.COO · Entity 3395 | Director | April 01, 2026 | April 06, 2026 |
| Intersect ENT, Inc.XENT · Entity 127294 | Director | May 13, 2022 | May 16, 2022 |
| Mobia Medical, Inc.MOBI · Entity 5669 | Director | May 07, 2026 | May 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COOPER COMPANIES, INC.
Report date April 01, 2026 · Filed April 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,767 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Exercise / conversion · Acquired 3,322 · Balance 12,767 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-01 · Exercise / conversion · Disposed 3,322 · Balance 0 F1: This award has no expiration date. Units will either vest or be forfeited. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,779 |
Reported balance
After 2026-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-01 · Grant · Acquired 3,779 · Balance 3,779 F1: This award has no expiration date. Units will either vest or be forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: This award has no expiration date. Units will either vest or be forfeited.
Intersect ENT, Inc.
Report date May 13, 2022 · Filed May 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-05-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-13 · Other · Disposed 16,383 · Balance 3,239 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Row 2 · 2022-05-13 · Other · Disposed 3,239 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-13 · Other · Disposed 3,220 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2029-06-03 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-13 · Other · Disposed 5,172 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2031-03-15 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-05-13 · Other · Disposed 3,390 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.50 · Expires 2031-06-02 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-05-13 · Other · Disposed 5,734 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2026-06-01 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-05-13 · Other · Disposed 9,666 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 · Expires 2024-07-08 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-05-13 · Other · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.05 · Expires 2028-06-04 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-05-13 · Other · Disposed 3,473 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2028-01-16 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-05-13 · Other · Disposed 2,797 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2025-06-03 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2022-05-13 · Other · Disposed 6,035 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. |
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2022-05-13 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2022-05-13 · Other · Disposed 7,570 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].
F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Mobia Medical, Inc.
Report date May 07, 2026 · Filed May 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 125,000 |
Reported balance
After 2026-05-11 transaction · row 1
1 source rowRow 1 · 2026-05-11 · Purchase · Acquired 125,000 · Balance 125,000 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-05-07 | Direct | 31,520 |
Reported balance
After 2026-05-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-07 · Grant · Acquired 31,520 · Balance 31,520 F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
HANGER, INC.
Report date October 03, 2022 · Filed October 04, 2022
Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-03 transaction · row 1
1 source rowRow 1 · 2022-10-03 · Disposition to issuer · Disposed 67,851 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 38,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73 | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2019 Filed Jan 18, 2019 17:36 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Option (right to buy) · Derivative | 3,220 | $0.00 Strike: $28.58 | $0.00 |
DisclosureSEC source: 0001562180-19-000368 · primarydocument.xml · derivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,220 Underlying: Common Stock · 3,220 shares Expires 2029-01-15 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2019. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 17:20 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 3,473 | $0.00 Strike: $42.05 | $0.00 |
DisclosureSEC source: 0001562180-18-002919 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,473 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 5, 2018. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 17:20 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 1,514 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-18-002919 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,060 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 5, 2019. F2 · balance_after: Includes 1,514 RSUs. Read SEC document |
| May 16, 2018 Filed May 17, 2018 13:57 UTC | HANGER, INC. HNGR · Entity 14115 | GrantCommon Stock | 7,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-024375 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,309 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 16, 2019, subject to certain provisions of the Plan. Read SEC document |
| January 17, 2018 Filed Jan 19, 2018 17:18 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 2,797 | $0.00 Strike: $33.95 | $0.00 |
DisclosureSEC source: 0001562180-18-000371 · primarydocument.xml · derivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,797 Underlying: Common Stock · 2,797 shares Expires 2028-01-16 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2018. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:29 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 6,035 | $0.00 Strike: $26.05 | $0.00 |
DisclosureSEC source: 0001562180-17-002198 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,035 Underlying: Common Stock · 6,035 shares Expires 2027-05-31 F2 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 1, 2017. Read SEC document |
| June 01, 2017 Filed Jun 5, 2017 19:29 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantCommon Stock | 2,546 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-17-002198 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,546 F1 · security: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 1, 2018. Read SEC document |
| May 19, 2017 Filed May 23, 2017 17:59 UTC | HANGER, INC. HGR · Entity 14115 | GrantCommon Stock | 10,964 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-022027 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,637 F1 · shares: Consists of shares of restricted stock granted under the Company's 2016 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 19, 2018, subject to certain provisions of the Plan. Read SEC document |
| January 18, 2017 Filed Jan 20, 2017 19:36 UTC | Intersect ENT, Inc. XENT · Entity 127294 | GrantStock Options (Right to buy) · Derivative | 7,570 | $0.00 Strike: $13.05 | $0.00 |
DisclosureSEC source: 0001562180-17-000294 · primarydocument.xml · derivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,570 Underlying: Common Stock · 7,570 shares Expires 2027-01-17 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.